Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in NAFLD and T2D
NCT02964715Phase 4Unknown
- Sponsor
- Universiti Malaya
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in Nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM), sponsored by Universiti Malaya. Primary endpoints: Change in histological Grade (NASH CRN Score) at 6 months and Change in serum FGF 21 at 6 months. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02964715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964715.